Molecular imaging in drug discovery and development

Imaging sciences have grown exponentially during the past three decades, and many techniques, such as magnetic resonance imaging, nuclear tomographic imaging and X-ray computed tomography, have become indispensable in clinical use. Advances in imaging technologies and imaging probes for humans and for small animals are now extending the applications of imaging further into drug discovery and development, and have the potential to considerably accelerate the process. This review summarizes some of the recent developments in conventional and molecular imaging, and highlights their impact on drug discovery.

[1]  M. Sherman,et al.  A Preliminary Report , 1953 .

[2]  E. Valtonen.  An experimental study on mice. , 1961, Acta pathologica et microbiologica Scandinavica. Supplement.

[3]  M. Rudin,et al.  Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging. , 1986, Stroke.

[4]  B. Rosen,et al.  Dynamic imaging with lanthanide chelates in normal brain: Contrast due to magnetic susceptibility effects , 1988, Magnetic resonance in medicine.

[5]  J. Kucharczyk,et al.  Magnetic resonance imaging of diffusion and perfusion , 1991, Topics in magnetic resonance imaging : TMRI.

[6]  N. Alpert,et al.  Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography , 1993, Antimicrobial Agents and Chemotherapy.

[7]  R. Blasberg,et al.  Imaging the expression of transfected genes in vivo. , 1995, Cancer research.

[8]  M D King,et al.  Identification of Collaterally Perfused Areas following Focal Cerebral Ischemia in the Rat by Comparison of Gradient Echo and Diffusion-Weighted MRI , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  N. Alpert,et al.  Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. , 1996, The Journal of pharmacology and experimental therapeutics.

[10]  J. W. Hastings,et al.  Chemistries and colors of bioluminescent reactions: a review. , 1996, Gene.

[11]  N. Alpert,et al.  Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography , 1996, Antimicrobial agents and chemotherapy.

[12]  Masafumi Oshiro,et al.  Visualizing Gene Expression in Living Mammals Using a Bioluminescent Reporter , 1997, Photochemistry and photobiology.

[13]  B. Teicher.  Cancer Therapeutics , 1997, Cancer Drug Discovery and Development.

[14]  P K Banerjee,et al.  Noninvasive methods for quantitating blood time-activity curves from mouse PET images obtained with fluorine-18-fluorodeoxyglucose. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  David A. Cheresh,et al.  Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging , 1998, Nature Medicine.

[16]  J S Fowler,et al.  Positron Emission Tomography Studies of Dopamine‐Enhancing Drugs , 1999, Journal of clinical pharmacology.

[17]  D. Bornhop,et al.  Fluorescent tissue site-selective lanthanide chelate, Tb-PCTMB for enhanced imaging of cancer. , 1999, Analytical chemistry.

[18]  H. Burns,et al.  Positron emission tomography neuroreceptor imaging as a tool in drug discovery, research and development. , 1999, Current opinion in chemical biology.

[19]  S. Cherry,et al.  Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Libby,et al.  MRI of rabbit atherosclerosis in response to dietary cholesterol lowering. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[21]  Markus Rudin,et al.  Magnetic resonance angiography of the rat cerebrovascular system without the use of contrast agents , 1999, NMR in biomedicine.

[22]  J. Hietala.  Ligand-receptor interactions as studied by PET: implications for drug development. , 1999, Annals of medicine.

[23]  R. Weissleder,et al.  In vivo assessment of vascular endothelial growth factor‐induced angiogenesis , 1999, International journal of cancer.

[24]  T. Reese,et al.  In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives , 1999, NMR in biomedicine.

[25]  J. Hoffman,et al.  Role of imaging in clinical trials of antiangiogenesis therapy in oncology. , 2000, Academic radiology.

[26]  R. Dasari,et al.  Prospects for in vivo Raman spectroscopy , 2000 .

[27]  M E Phelps,et al.  Positron emission tomography provides molecular imaging of biological processes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R. Gillies,et al.  Applications of magnetic resonance in model systems: cancer therapeutics. , 2000, Neoplasia.

[29]  Anna Moore,et al.  In vivo magnetic resonance imaging of transgene expression , 2000, Nature Medicine.

[30]  A. Waarde,et al.  Measuring receptor occupancy with PET. , 2000, Current pharmaceutical design.

[31]  Ralph Weissleder,et al.  Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells , 2000, Nature Biotechnology.

[32]  Non-invasive radiotracer imaging as a tool for drug development. , 2000, Current pharmaceutical design.

[33]  J. Hietala,et al.  PET studies of brain monoamine transporters. , 2000, Current pharmaceutical design.

[34]  T L Chenevert,et al.  Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  L. Svaasand,et al.  Non-invasive in vivo characterization of breast tumors using photon migration spectroscopy. , 2000, Neoplasia.

[36]  S. Achilefu,et al.  Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. , 2001, Journal of biomedical optics.

[37]  B. Chance.  Near-infrared (NIR) optical spectroscopy characterizes breast tissue hormonal and age status. , 2001, Academic radiology.

[38]  X. Li,et al.  Synthesis and NMR studies of new DOTP-like lanthanide(III) complexes containing a hydrophobic substituent on one phosphonate side arm. , 2001, Inorganic chemistry.

[39]  C. Peterfy.  Magnetic resonance imaging of rheumatoid arthritis: the evolution of clinical applications through clinical trials. , 2001, Seminars in arthritis and rheumatism.

[40]  S. Gambhir,et al.  Optical imaging of Renilla luciferase reporter gene expression in living mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  B. Gulyás,et al.  PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. , 2001, Current pharmaceutical design.

[42]  G. Zonios,et al.  Skin melanin, hemoglobin, and light scattering properties can be quantitatively assessed in vivo using diffuse reflectance spectroscopy. , 2001, The Journal of investigative dermatology.

[43]  S. Osman,et al.  Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. , 2001, Current pharmaceutical design.

[44]  Y. Kajimoto,et al.  Development and Clinical Application of Near-Infrared Surgical Microscope: Preliminary Report , 2001, Minimally invasive neurosurgery : MIN.

[45]  S R Cherry,et al.  Detector development for microPET II: a 1 microl resolution PET scanner for small animal imaging. , 2001, Physics in medicine and biology.

[46]  R. B. Campbell,et al.  In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy , 2001, Nature Medicine.

[47]  H. Honda,et al.  Detection of human gastric cancer in resected specimens using a novel infrared fluorescent anti-human carcinoembryonic antigen antibody with an infrared fluorescence endoscope in vitro. , 2001, Endoscopy.

[48]  Osama Mawlawi,et al.  Differential Occupancy of Somatodendritic and Postsynaptic 5HT1A Receptors by Pindolol: A Dose-Occupancy Study with [11C]WAY 100635 and Positron Emission Tomography in Humans , 2001, Neuropsychopharmacology.

[49]  L. Pilowsky.  Probing targets for antipsychotic drug action with PET and SPET receptor imaging , 2001, Nuclear medicine communications.

[50]  Yu-Shin Ding,et al.  Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer’s dementia , 2001, Biological Psychiatry.

[51]  Ralph Weissleder,et al.  In vivo molecular target assessment of matrix metalloproteinase inhibition , 2001, Nature Medicine.

[52]  Jan Passchier,et al.  Visualisation of serotonin-1A (5-HT1A) receptors in the central nervous system , 2001, European Journal of Nuclear Medicine.

[53]  R. Gillies,et al.  The physiological environment in cancer vascularization, invasion and metastasis. , 2001, Novartis Foundation symposium.

[54]  S. Cherry,et al.  Fundamentals of Positron Emission Tomography and Applications in Preclinical Drug Development , 2001, Journal of clinical pharmacology.

[55]  W. Semmler,et al.  Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands , 2001, Nature Biotechnology.

[56]  M. Rudin,et al.  From anatomy to the target: Contributions of magnetic resonance imaging to preclinical pharmaceutical research , 2001, The Anatomical record.

[57]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[58]  R. Weissleder.  Scaling down imaging: molecular mapping of cancer in mice , 2002, Nature Reviews Cancer.

[59]  Vasilis Ntziachristos,et al.  Would near-infrared fluorescence signals propagate through large human organs for clinical studies? , 2002, Optics letters.

[60]  Dai Fukumura,et al.  Dissecting tumour pathophysiology using intravital microscopy , 2002, Nature Reviews Cancer.

[61]  M. Rausch,et al.  Recovery of function in cytoprotected cerebral cortex in rat stroke model assessed by functional MRI , 2002, Magnetic resonance in medicine.

[62]  Vasilis Ntziachristos,et al.  High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. , 2002, Bioconjugate chemistry.

[63]  Ralph Weissleder,et al.  Feasibility of in vivo multichannel optical imaging of gene expression: experimental study in mice. , 2002, Radiology.

[64]  Vasilis Ntziachristos,et al.  Would near-infrared fluorescence signals propagate through large human organs for clinical studies? Errata. , 2002, Optics letters.

[65]  M. Rausch,et al.  In‐vivo visualization of phagocytotic cells in rat brains after transient ischemia by USPIO , 2002, NMR in biomedicine.

[66]  T. O'Dorisio,et al.  Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. , 2002, Seminars in nuclear medicine.

[67]  J. Lindon,et al.  Metabonomics: a platform for studying drug toxicity and gene function , 2002, Nature Reviews Drug Discovery.

[68]  Ralph Weissleder,et al.  Magnetic relaxation switches capable of sensing molecular interactions , 2002, Nature Biotechnology.

[69]  Jean-Philippe Galons,et al.  Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. , 2002, Neoplasia.

[70]  A Del Guerra,et al.  Advances in animal PET scanners. , 2002, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[71]  Ralph Weissleder,et al.  Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. , 2002, Bioconjugate chemistry.

[72]  G. Hortobagyi,et al.  Angiogenesis modulation in cancer research: novel clinical approaches , 2002, Nature Reviews Drug Discovery.

[73]  R. Weissleder,et al.  Fluorescence molecular tomography resolves protease activity in vivo , 2002, Nature Medicine.

[74]  Gary D Luker,et al.  Molecular imaging of gene expression and protein function in vivo with PET and SPECT , 2002, Journal of magnetic resonance imaging : JMRI.

[75]  T. Jones,et al.  Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for Pre-phase I positron emission tomography studies in cancer patients , 2002, British Journal of Cancer.

[76]  M Bergström,et al.  Positron emission tomography and brain monoamine neurotransmission -- entries for study of drug interactions. , 2002, Current pharmaceutical design.

[77]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[78]  Ralph Weissleder,et al.  Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. , 2002, Gastroenterology.

[79]  Woo Kyung Moon,et al.  A Receptor‐Targeted Near‐Infrared Fluorescence Probe for In Vivo Tumor Imaging , 2002, Chembiochem : a European journal of chemical biology.

[80]  Vasilis Ntziachristos,et al.  Shedding light onto live molecular targets , 2003, Nature Medicine.

[81]  Lillian S Kao,et al.  Trials and tribulations: current challenges in conducting clinical trials. , 2003, Archives of surgery.